{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Umbilical+Cord+Blood+After+Myeloablative+Conditioning", "query": { "intervention": "Umbilical Cord Blood After Myeloablative Conditioning" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 36, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Umbilical+Cord+Blood+After+Myeloablative+Conditioning&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-05T14:39:36.864Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00719849", "title": "Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "total body irradiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "69 Years", "sex": "ALL", "summary": "Up to 69 Years" }, "enrollment_count": 13, "start_date": "2005-11", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2017-06-14", "last_synced_at": "2026-10-05T14:39:36.864Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00719849" }, { "nct_id": "NCT02354417", "title": "A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "Biological: ProHema-CB", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 3, "start_date": "2014-12", "completion_date": "2017-02", "has_results": true, "last_update_posted_date": "2018-10-10", "last_synced_at": "2026-10-05T14:39:36.864Z", "location_count": 2, "location_summary": "Duarte, California • Boston, Massachusetts", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02354417" }, { "nct_id": "NCT00568633", "title": "Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia, Myeloid", "Leukemia", "Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "Allogeneic HSCT", "type": "PROCEDURE" }, { "name": "Anti-thymocyte globulin (ATG)", "type": "DRUG" }, { "name": "Cyclosporine (CSP)", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "Total lymphoid irradiation (TLI)", "type": "RADIATION" }, { "name": "Methylprednisolone sodium succinate", "type": "DRUG" }, { "name": "Best standard care", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "50 Years to 75 Years" }, "enrollment_count": 58, "start_date": "2007-08", "completion_date": "2015-12-31", "has_results": true, "last_update_posted_date": "2019-09-24", "last_synced_at": "2026-10-05T14:39:36.864Z", "location_count": 5, "location_summary": "Hayward, California • Los Angeles, California • Sacramento, California + 2 more", "locations": [ { "city": "Hayward", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00568633" }, { "nct_id": "NCT00309842", "title": "Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Myelofibrosis", "MDS", "Refractory Anemia", "Chronic Lymphocytic Leukemia", "Prolymphocytic Leukemia", "Non-Hodgkin's Lymphoma", "Leukemia", "Lymphoma", "Multiple Myeloma", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "total-body irradiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "55 Years", "sex": "ALL", "summary": "Up to 55 Years" }, "enrollment_count": 213, "start_date": "2005-07-28", "completion_date": "2019-11-22", "has_results": true, "last_update_posted_date": "2020-09-10", "last_synced_at": "2026-10-05T14:39:36.864Z", "location_count": 2, "location_summary": "Minneapolis, Minnesota • Seattle, Washington", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00309842" }, { "nct_id": "NCT00676806", "title": "A Phase II Study of Umbilical Cord Blood Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma", "Aplastic Anemia" ], "interventions": [ { "name": "Umbilical Cord Blood After Myeloablative Conditioning", "type": "BIOLOGICAL" }, { "name": "Umbilical Cord Blood After Reduced-Intensity Conditioning", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Tufts Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 7, "start_date": "2005-07", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2017-06-01", "last_synced_at": "2026-10-05T14:39:36.864Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00676806" }, { "nct_id": "NCT00354172", "title": "Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "natural killer cell (NK) therapy", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "Umbilical Cord Blood Transplantation (UCBT)", "type": "PROCEDURE" }, { "name": "Total body irradiation (TBI)", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "45 Years", "sex": "ALL", "summary": "Up to 45 Years" }, "enrollment_count": 16, "start_date": "2006-02", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-10-05T14:39:36.864Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00354172" }, { "nct_id": "NCT01175785", "title": "Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Previously Treated Myelodysplastic Syndromes", "Refractory Anemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation", "Relapsing Chronic Myelogenous Leukemia", "Secondary Myelodysplastic Syndromes" ], "interventions": [ { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "ex vivo-expanded cord blood progenitor cell infusion", "type": "BIOLOGICAL" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "Nohla Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "45 Years", "sex": "ALL", "summary": "6 Months to 45 Years" }, "enrollment_count": 15, "start_date": "2010-08", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-10-05T14:39:36.864Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01175785" }, { "nct_id": "NCT02118311", "title": "Treg Cells for AGVHD in Non-myeloablative UCB Transplant", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "T Regulatory cells", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 0, "start_date": "2016-06", "completion_date": "2018-09", "has_results": false, "last_update_posted_date": "2017-12-02", "last_synced_at": "2026-10-05T14:39:36.864Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02118311" }, { "nct_id": "NCT00556452", "title": "Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Hodgkin Lymphoma", "Non-Hodgkin Lymphoma", "Multiple Myeloma", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Clofarabine/Busulfan x 4", "type": "DRUG" }, { "name": "Peripheral blood stem cell transplant", "type": "PROCEDURE" }, { "name": "Total Lymphoid Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 46, "start_date": "2007-10", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-10-05T14:39:36.864Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00556452" }, { "nct_id": "NCT00539656", "title": "Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Leukemia, Lymphoblastic, Acute", "Leukemia, Bilineage, Acute", "Leukemia, Myeloid, Chronic" ], "interventions": [ { "name": "Ex vivo expansion of cord blood", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "55 Years", "sex": "ALL", "summary": "6 Months to 55 Years" }, "enrollment_count": 3, "start_date": "2007-12-20", "completion_date": "2009-10-20", "has_results": true, "last_update_posted_date": "2020-02-18", "last_synced_at": "2026-10-05T14:39:36.864Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00539656" } ] }